Novartis To Settle Sales Reps' OT Claims For $99M
Novartis Pharmaceuticals Corp. has agreed to pay $99 million to resolve claims brought in New York federal court by a class of drug sales representatives who allege they were misclassified as...To view the full article, register now.
Already a subscriber? Click here to view full article